Endoscopic anti-reflux treatment for gastroesophageal reflux disease
Abstract
Gastroesophageal reflux disease (GERD) is a heterogeneous condition with substantial diagnostic and therapeutic complexities. Endoscopic anti-reflux therapies have emerged as minimally invasive options positioned between pharmacological therapy and surgical fundoplication. However, their optimal role remains incompletely defined. Endoscopic anti-reflux therapies encompass distinct mechanistic categories, including mucosal remodeling-based interventions, neuromodulatory therapy, and endoscopic fundoplication. Among these, transoral incisionless fundoplication has the most clearly defined role in current international guidelines for carefully selected patients with mild-to-moderate GERD, predominant regurgitation, and minimal anatomical disruption. In contrast, radiofrequency-based therapy is generally confined to a limited symptom-oriented role. Anti-reflux mucosal interventions represent an evolving approach with encouraging results from observational studies and meta-analyses; however, their use remains limited by the heterogeneity of techniques and lack of robust randomized evidence. This review provides an evidence-based appraisal of contemporary endoscopic anti-reflux therapies, focusing on the mechanistic rationale, patient selection, clinical outcomes, and guideline positioning. Accurate diagnosis and phenotypic classification are essential. Objective confirmation of pathological reflux, assessment of the esophagogastric junction anatomy, and evaluation of esophageal…
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.